CytoDyn Inc. FY 2026: Net income $(42.7M), EPS $(0.03) — 10-K Summary
CytoDyn Inc. reported a net loss of $42.7M for fiscal 2026, a significant decline from a $3.7M net income in 2025. The company's cash reserves stood at $11.9M, with working capital and accumulated deficits raising concerns about its ability to continue operations. CytoDyn cited clinical development progress and strategic partnerships as key highlights.
How this was made
The 30-second read
Why it matters
The earnings miss and going‑concern language suggest heightened risk for shareholders.
Market read
Earnings release for a micro‑cap biotech with a material loss and liquidity concerns.
What to watch
Potential upside from upcoming Phase 2 colorectal cancer data and new AI drug‑discovery partnership.
Background
CytoDyn filed its FY 2026 10‑K, highlighting a net loss, cash position, and ongoing clinical programs.
Ticker impact
CytoDyn reported a FY 2026 consolidated net loss of $42.7M and a diluted loss per share of $0.03, raising going‑concern doubts.
downward pressure, potential short‑term decline
Earnings miss and liquidity concerns are material negative catalysts for a micro‑cap biotech.
Market effects
Biotech sector may see broader risk‑off sentiment as small‑cap earnings miss.
US small‑cap biotech indices could dip.
Limited, primarily affects US micro‑cap biotech investors.
Counterpoint
If the company secures additional financing, the stock could rebound despite the loss.
Key entities
- companyCytoDyn Inc.
US‑listed biotech (NASDAQ: CYDY) reporting FY 2026 results.
